Want to see FR:ALMKT full AI Analyst Report?

MAUNA KEA TECHNOLOGIES (ALMKT) Price & Analysis

1 Followers

ALMKT Stock Chart & Stats

€0.15

€0.00(0.00%)

At close: Jul 27 4:00 PM EDT

€0.15

€0.00(0.00%)

Day’s Range― - ―

52-Week Range€0.07 - €0.23

Previous CloseN/A

Volume331.86K

Average Volume (3M)830.17K

Market Cap

€30.66M

Enterprise Value€14.00

Total Cash (Recent Filing)€4.97M

Total Debt (Recent Filing)€12.08M

Price to Earnings (P/E)7.7

Beta0.89

Next Earnings

Oct 08, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.02

Shares Outstanding195,260,220

10 Day Avg. Volume1,028,958

30 Day Avg. Volume830,169

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)-2.65

Price to Sales (P/S)1.55

P/FCF Ratio-3.24

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.01

Revenue Forecast (FY)€7.75M

Bulls Say, Bears Say

Bulls Say

High Gross MarginsSustained ~75% gross margins indicate strong unit economics for the CLE platform and probes. High product-level margin supports long-term profitability potential as the installed base grows and recurring consumable sales scale, providing durable margin tailwinds if operating costs are controlled.

Revenue Rebound And Demand RecoveryA 57.5% revenue rebound shows the company can regain clinical demand and suggests product-market fit for its endomicroscopy systems. Durable installed-base growth drives recurring consumable and service revenue, supporting sustainable top-line expansion if adoption continues across endoscopy centers.

Material Debt Reduction In 2025Significant deleveraging reduces near-term refinancing pressure and interest burden, improving financial flexibility. Lower gross debt enhances the firm's ability to fund commercialization and support the installed base, making strategic investments or securing partnerships more achievable over the medium term.

Bears Say

Persistent Negative Cash FlowConsistent operating and free cash outflows mean the business relies on external funding or balance-sheet actions to operate. This structural cash burn limits reinvestment, risks dilution or additional debt, and constrains the company’s ability to scale commercial efforts or weather adverse reimbursement or sales cycles.

Deeply Negative Operating ProfitabilityAn ~-83% operating margin signals that operating costs (R&D, sales, G&A) far outpace revenues. Unless the cost base is materially reduced or revenue scales rapidly, profitability is structurally weak, making net income improvements fragile and dependent on non-operational items rather than sustainable operating performance.

Negative Shareholders' EquityPersistent negative equity reflects accumulated deficits and weak capital buffer, limiting financial flexibility. This structural deficit raises solvency and refinancing risk, can complicate raising equity or negotiating favorable partner terms, and increases vulnerability to shocks despite recent debt reduction.

MAUNA KEA TECHNOLOGIES News

Mauna Kea boosts pancreatic cyst diagnosis accuracy with Cellvizio and AI

An announcement from MAUNA KEA TECHNOLOGIES ( ($FR:ALMKT) ) is now available. Mauna Kea Technologies reported new clinical...

6d ago

Mauna Kea Technologies Posts Strong H1 2026 Growth, Bolsters Path to Profitability

MAUNA KEA TECHNOLOGIES ( ($FR:ALMKT) ) just unveiled an announcement. Mauna Kea Technologies reported first-half 2026 revenue of...

12d ago

ALMKT FAQ

What was MAUNA KEA TECHNOLOGIES’s price range in the past 12 months?

MAUNA KEA TECHNOLOGIES lowest stock price was €0.07 and its highest was €0.23 in the past 12 months.

What is MAUNA KEA TECHNOLOGIES’s market cap?

MAUNA KEA TECHNOLOGIES’s market cap is €30.66M.

When is MAUNA KEA TECHNOLOGIES’s upcoming earnings report date?

MAUNA KEA TECHNOLOGIES’s upcoming earnings report date is Oct 08, 2026 which is in 66 days.

How were MAUNA KEA TECHNOLOGIES’s earnings last quarter?

MAUNA KEA TECHNOLOGIES released its earnings results on Apr 22, 2026. The company reported €0.19 earnings per share for the quarter, beating the consensus estimate of N/A by €0.19.

Is MAUNA KEA TECHNOLOGIES overvalued?

According to Wall Street analysts MAUNA KEA TECHNOLOGIES’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does MAUNA KEA TECHNOLOGIES pay dividends?

MAUNA KEA TECHNOLOGIES does not currently pay dividends.

What is MAUNA KEA TECHNOLOGIES’s EPS estimate?

MAUNA KEA TECHNOLOGIES’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does MAUNA KEA TECHNOLOGIES have?

MAUNA KEA TECHNOLOGIES has 195,260,220 shares outstanding.

What happened to MAUNA KEA TECHNOLOGIES’s price movement after its last earnings report?

MAUNA KEA TECHNOLOGIES reported an EPS of €0.19 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.622%.

Which hedge fund is a major shareholder of MAUNA KEA TECHNOLOGIES?

Currently, no hedge funds are holding shares in FR:ALMKT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

MAUNA KEA TECHNOLOGIES

Mauna Kea Technologies SA operates as a medical device enterprise, producing and distributing its offerings throughout Europe and worldwide. Its product line serves various medical specialties such as gastroenterology, pulmonology, and urology. Central to its portfolio is Cellvizio, an in vivo cellular imaging platform that delivers real-time data. This innovative system assists medical practitioners in tracking disease evolution, evaluating immediate physiological responses, delineating ambiguous tissue areas, and providing guidance during surgical procedures. Founded in 2000, the company's headquarters are situated in Paris, France.